X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PIRAMAL ENTERPRISES - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PIRAMAL ENTERPRISES DIVIS LABORATORIES/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 38.4 10.4 368.3% View Chart
P/BV x 6.2 1.8 346.7% View Chart
Dividend Yield % 0.7 0.9 79.3%  

Financials

 DIVIS LABORATORIES   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
PIRAMAL ENTERPRISES
Mar-18
DIVIS LABORATORIES/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,1423,083 37.0%   
Low Rs5331,902 28.0%   
Sales per share (Unadj.) Rs146.6589.7 24.9%  
Earnings per share (Unadj.) Rs33.0284.0 11.6%  
Cash flow per share (Unadj.) Rs38.4310.5 12.4%  
Dividends per share (Unadj.) Rs10.0025.00 40.0%  
Dividend yield (eoy) %1.21.0 119.1%  
Book value per share (Unadj.) Rs222.81,467.0 15.2%  
Shares outstanding (eoy) m265.47180.27 147.3%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x5.74.2 135.2%   
Avg P/E ratio x25.38.8 288.9%  
P/CF ratio (eoy) x21.88.0 271.7%  
Price / Book Value ratio x3.81.7 221.2%  
Dividend payout %30.38.8 343.9%   
Avg Mkt Cap Rs m222,318449,332 49.5%   
No. of employees `00010.86.8 157.3%   
Total wages/salary Rs m4,56119,881 22.9%   
Avg. sales/employee Rs Th3,616.015,535.6 23.3%   
Avg. wages/employee Rs Th423.82,905.4 14.6%   
Avg. net profit/employee Rs Th814.97,482.5 10.9%   
INCOME DATA
Net Sales Rs m38,915106,310 36.6%  
Other income Rs m1,1342,595 43.7%   
Total revenues Rs m40,049108,906 36.8%   
Gross profit Rs m12,61751,599 24.5%  
Depreciation Rs m1,4254,773 29.9%   
Interest Rs m1329,783 0.0%   
Profit before tax Rs m12,31319,638 62.7%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,543-28,764 -12.3%   
Profit after tax Rs m8,77051,203 17.1%  
Gross profit margin %32.448.5 66.8%  
Effective tax rate %28.8-146.5 -19.6%   
Net profit margin %22.548.2 46.8%  
BALANCE SHEET DATA
Current assets Rs m45,351118,154 38.4%   
Current liabilities Rs m6,507462,260 1.4%   
Net working cap to sales %99.8-323.7 -30.8%  
Current ratio x7.00.3 2,726.7%  
Inventory Days Days12727 476.7%  
Debtors Days Days9547 204.4%  
Net fixed assets Rs m21,160113,727 18.6%   
Share capital Rs m531361 147.3%   
"Free" reserves Rs m58,625264,093 22.2%   
Net worth Rs m59,156264,454 22.4%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m67,832726,834 9.3%  
Interest coverage x926.81.7 55,853.6%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.1 392.2%   
Return on assets %12.911.1 116.2%  
Return on equity %14.819.4 76.6%  
Return on capital %20.810.3 202.2%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35915,110 214.2%   
Fx outflow Rs m9,0424,298 210.4%   
Net fx Rs m23,31710,813 215.6%   
CASH FLOW
From Operations Rs m7,759-159,666 -4.9%  
From Investments Rs m-4,783-17,677 27.1%  
From Financial Activity Rs m-3,142186,503 -1.7%  
Net Cashflow Rs m-1669,364 -1.8%  

Share Holding

Indian Promoters % 52.0 52.9 98.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 4.0 295.0%  
FIIs % 19.0 26.6 71.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 16.5 104.2%  
Shareholders   31,796 93,274 34.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - CIPLA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS